CS-1887

CS-1887 - Names and Identifiers

Name	N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxa
Synonyms	CS-1887 GLPG0634 GLPG634 analog GLPG0634 analog GLPG0634 analog, Filgotinib analog N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxa N-[5-[4-[(6-cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxaMide N-(5-(4-((6-cyanopyridin-3-yl)methoxy)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide N-[5-[4-[(6-Cyano-3-pyridinyl)Methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxaMide (GLPG0634) N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxamide GLPG0634 analogue GLPG0634 N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxamide
CAS	1206101-20-3

CS-1887 - Physico-chemical Properties

Molecular Formula	C23H18N6O2
Molar Mass	410.43
Storage Condition	-20°C
In vitro study	In cell lines, GLPG0634 inhibited JAK1/JAK3/γc signaling induced by IL-2 and IL-4 and JAK1/TYK2 type II receptor signaling induced by IFN-αB2 with an IC50 in the range of 150 to 760 nM. At the cellular level, GLPG0634 is more selective for JAK/STAT signaling comprising JAK1 than JAK2 kinase. In addition, GLPG0634 also inhibits the proliferation of Th1,Th2, and Th17 cells.
In vivo study	After oral administration, the absolute bioavailability was moderate in rats (45%) and higher in mice (100%). GLPG0634 (30 mg/kg per day (RAT);50 mg/kg twice a day (mouse)) dose-dependently reduces inflammation, cartilage, and bone degradation.

CS-1887 - Preparation solution concentration reference

	1mg	5mg	10mg
1 mM	2.436 ml	12.182 ml	24.365 ml
5 mM	0.487 ml	2.436 ml	4.873 ml
10 mM	0.244 ml	1.218 ml	2.436 ml
5 mM	0.049 ml	0.244 ml	0.487 ml

Last Update：2024-01-02 23:10:35

CS-1887 - Introduction

GLPG0634 is a selective small molecule Janus kinase (JAK) inhibitor that regulates immune and inflammatory processes by inhibiting JAK1 and JAK2 activity. It is studied for the treatment of a series of autoimmune diseases, such as rheumatoid arthritis, bone hyperplasia and so on.

About the preparation method, N-[5-[4-[(6-Cyano-3-pyridinyl)methoxy]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl] cyclopropanecarboxa is prepared in the laboratory by synthetic organic chemistry methods. Specific synthetic routes and methods may require reference to relevant research literature or patents.

Last Update：2024-04-09 21:49:45